Eloxx Pharmaceuticals, Inc.
ELOX
$0.0001
$0.000.00%
| Weiss Ratings | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -669,826.68 | |||
| Price History | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -99.99% | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -99.99% | |||
| 2-Year Total Return | -100.00% | |||
| 3-Year Total Return | -100.00% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | -99.99% | |||
| 52-Week Low % Change | 9,900.00% | |||
| Price | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.15 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Aug 14, 2024 | |||
| 52-Week High Price (Date) | Apr 30, 2024 | |||
| Valuation | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 330.00 | |||
| Enterprise Value | 13.95M | |||
| Price/Earnings (TTM) | 0.00 | |||
| Earnings Per Share (TTM) | -9.07 | |||
| Earnings Per Share Growth | -53.07% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -0.73 | |||
| Enterprise Value/EBIT | -0.72 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 2.75M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 577 5300 | |||
| Address | 480 Arsenal Way Watertown, MA 02472 | |||
| Website | www.eloxxpharma.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -73.24% | |||
| Return on Equity | -- | |||
| Income Statement | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -19.24M | |||
| EBIT (TTM) | -19.29M | |||
| Net Income (TTM) | -20.48M | |||
| Net Income Avl. to Common (TTM) | -20.48M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 52.16% | |||
| EPS Diluted (TTM) | -9.07 | |||
| EPS Diluted Growth (Q YOY) | 62.25% | |||
| Balance Sheet | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 4.78M | |||
| Cash Per Share (Q) | $1.74 | |||
| Total Current Assets (Q) | 5.63M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -20.05M | |||
| Current Ratio (Q) | 0.240 | |||
| Book Value Per Share (Q) | -$6.53 | |||
| Total Assets (Q) | 6.04M | |||
| Total Current Liabilities (Q) | 23.47M | |||
| Total Debt (Q) | 18.72M | |||
| Total Liabilities (Q) | 26.09M | |||
| Total Common Equity (Q) | -20.05M | |||
| Cash Flow | ELOX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 258.00K | |||
| Cash from Financing (TTM) | -2.09M | |||
| Net Change in Cash (TTM) | -19.82M | |||
| Levered Free Cash Flow (TTM) | -8.25M | |||
| Cash from Operations (TTM) | -17.99M | |||
